Just thinking out aloud here, the announcement states:
"may be an effective and safe treatment option for GI malignancies.
The most common types of GI cancers are:
Esophageal cancer
Gastric (stomach) cancer
Colorectal cancer
Pancreatic cancer
Liver cancer
Gastrointestinal stromal tumors
Anal cancer
Does our cohort have any additional ones of these along with those patients with bile duct cancer that would then increase confidence in the treatment if the latest data points to success?
Ann: Imugene to present at 2024 Cholangiocarcinoma Conference, page-52
-
- There are more pages in this discussion • 170 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $334.7M | |||
| Open | High | Low | Value | Volume |
| 4.6¢ | 4.6¢ | 4.4¢ | $417.0K | 9.281M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 37 | 6074903 | 4.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.5¢ | 362283 | 5 |
View Market Depth
| Last trade - 16.10pm 07/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |